

Registry of procalcitonin-guided antibiotic therapy in patients with lower respiratory tract infections outside of study conditions: Pro-REAL - a real-life" survey

Submission date 18/09/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 16/10/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 17/07/2012	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Werner Albrich

Contact details
Tellstrasse
Kantonsspital Aarau
Aarau
Switzerland
5001

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title

Acronym

ProREAL

Study objectives

Duration of antibiotic therapy for patients with lower respiratory tract infections can be shortened by application of a procalcitonin-based algorithm in real-life conditions.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Switzerland:

1. Ethics Committee of Aargau (Kantonale Ethikkommission Kanton Aargau) (EKAG), approved on 06/10/2008 (ref: 2006/48)
2. Ethics Committee of Basel (Ethikkommission Beider Basel) (EKBB), approved on 29/07/2008 (ref: 236/08)

Ethics approvals for trial centres in France: Pending as of 18/09/2009

Study design

Observational prospective longitudinal study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Respiratory tract infections

Interventions

The participants will be contacted approximately 30 days after the start of the treatment to conduct a telephone interview lasting approximately 10 minutes. They will be asked about any persisting complaints, possible side-effects of the antibiotics (such as diarrhoea and nausea) and recurrence of the respiratory tract infection with or without antibiotic treatment. They will also be asked whether they had to visit the GP or the hospital, and if so, how many times.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Duration of antibiotic treatment

All primary and secondary outcome measures will be assessed by a telephone interview 30 days after the start of the treatment.

Key secondary outcome(s)

1. Adherence to procalcitonin algorithm
2. Adverse medical outcomes (complications, mortality, relapse, intensive care unit [ICU] admission)
3. Antibiotic side effects
4. Length of hospital stay
5. Differences between procalcitonin (PCT) levels measured by KRYPTOR® and VIDAS®

All primary and secondary outcome measures will be assessed by a telephone interview 30 days after the start of the treatment.

Completion date

09/09/2011

Eligibility**Key inclusion criteria**

1. Both males and females, age >18
2. Lower respiratory tract infection (at least one respiratory symptom [cough, sputum production, dyspnea, tachypnea, pleuritic pain]) PLUS
3. One of the following auscultatory finding or sign of infection:
 - 3.1. Core body temperature >38°C or <36°C
 - 3.2. Shivers
 - 3.3. Leukocyte count >10 g/L or <4 g/L cells

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

10/09/2009

Date of final enrolment

09/09/2011

Locations

Countries of recruitment

France

Switzerland

Study participating centre

Tellstrasse

Aarau

Switzerland

5001

Sponsor information**Organisation**

BioMérieux (France)

ROR

<https://ror.org/03hf69k85>

Funder(s)**Funder type**

Hospital/treatment centre

Funder Name

Aarau Hospital (Switzerland)

Funder Name

BioMerieux (France) provides the procalcitonin test kits

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	14/05/2012		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes